The lure of a razor-sharp therapeutic focus has enticed AstraZeneca’s head of early clinical development, Tony Johnson, to take the top job at kidney disease…
ValiRx is approaching a pivotal point in its development as it waits for clinical results from two lead programs.
Boston biotech resTORbio raised $40 million aimed at taking its lead candidate for respiratory tract infections in elderly patients into phase 3.
AstraZeneca doubles down on Chinese business through a new drug development joint venture with a state-backed private equity firm.
Gamida Cell has named Julian Adams, Ph.D.—its current chair and chief scientific officer of Clal Biotech—as its new CEO.
Germano takes up the position 8 months after a shift in focus at Intrexon led him to give up the president post at the synthetic biology company.
Immunomedics has drawn a firm line under the disruption among its top management in recent months by hiring biotech veteran Michael Pehl.
Flushed with recent clinical trial wins, Apellis has moved quickly ahead with an initial public offering.
Shanghai-based biotech EOC Pharma has raised $32 million from Chinese investors to help it bring a series of cancer drugs to market.
We kick off a new long form series assessing the life science industry from its leaders with ex-Teva chief Jeremy Levin.